25,590 Pfizer Inc. $PFE Shares Bought by Americana Partners LLC

Americana Partners LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 500,769 shares of the biopharmaceutical company’s stock after buying an additional 25,590 shares during the period. Americana Partners LLC’s holdings in Pfizer were worth $14,282,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Aprio Wealth Management LLC grew its holdings in Pfizer by 1.3% during the third quarter. Aprio Wealth Management LLC now owns 42,281 shares of the biopharmaceutical company’s stock valued at $1,206,000 after purchasing an additional 533 shares during the last quarter. Fusion Capital LLC bought a new position in shares of Pfizer during the 3rd quarter worth about $200,000. Left Brain Wealth Management LLC increased its stake in Pfizer by 24.5% during the third quarter. Left Brain Wealth Management LLC now owns 15,454 shares of the biopharmaceutical company’s stock valued at $441,000 after acquiring an additional 3,037 shares during the period. Modera Wealth Management LLC increased its position in shares of Pfizer by 1.8% during the third quarter. Modera Wealth Management LLC now owns 51,828 shares of the biopharmaceutical company’s stock valued at $1,478,000 after purchasing an additional 900 shares during the period. Finally, Prosperitas Financial LLC increased its position in shares of Pfizer by 7.2% during the third quarter. Prosperitas Financial LLC now owns 10,562 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 706 shares during the period. Institutional investors own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analysts Set New Price Targets

A number of research analysts recently commented on PFE shares. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Scotiabank raised their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.65.

Pfizer Stock Up 1.8%

Shares of NYSE PFE opened at $30.48 on Friday. The firm’s 50-day simple moving average is $28.55 and its 200 day simple moving average is $26.79. The company has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a price-to-earnings-growth ratio of 2.03 and a beta of 0.32. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $30.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.